Trial Profile
A Phase 1, Open Label, Single Dose, Parallel Group Study To Evaluate The Plasma Pharmacokinetics Of Glasdegib (Pf-04449913) In Healthy Subjects With Normal Hepatic Function And In Subjects With Impaired Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Glasdegib (Primary)
- Indications Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 21 Mar 2020 Results assessing Glasdegib plasma exposure participants with moderate and severe hepatic impairment presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 01 May 2019 Status changed from recruiting to completed.